Protective effect of serum thymic factor, FTS, on cephaloridine-induced nephrotoxicity in rats.
Serum thymic factor (FTS), a thymic peptide hormone, has been reported to increase superoxide disumutase (SOD) levels in senescence-accelerated mice. In the present study, we examined the effect of FTS on cephaloridine (CER)-induced nephrotoxicity in vivo and in vitro. We previously reported that CER led to extracellular signal-regulated protein kinase (ERK) activation in the rat kidney. So, we also investigated whether FTS has an effect on ERK activation induced by CER. Treatment of male Sprague-Dawley rats with intravenous CER (1.2 g/kg) for 24 h markedly increased BUN and plasma creatinine levels and urinary excretion of glucose and protein, decreased creatinine clearance and also led to marked pathological changes in the proximal tubules, as revealed by electron micrographs. An increase in phosphorylated ERK (pERK) was detected in the nuclear fraction prepared from the rat kidney cortex 24 h after CER injection. Pretreatment of rats with FTS (50 microg/kg, i.v.) attenuated the CER-induced renal dysfunction and pathological damage. FTS also suppressed CER-induced ERK activation in the kidney. In vitro treatment of the established cell line, LLC-PK1 cells, with FTS significantly ameliorated CER-induced cell injury, as measured by lactate dehydrogenase (LDH) leakage. Our results, taken together with our previous report that MEK inhibitors ameliorated CER-induced renal cell injury and ERK activation induced by CER, suggest that FTS participates in protection from CER-induced nephrotoxicity by suppressing ERK activation induced by CER.
Kohda
Yuka
Y
Division of Pharmacology, Osaka University of Pharmaceutical Sciences, Japan. kohda@gly.oups.ac.jp
Matsunaga
Yoshiko
Y
Yonogi
Katsuya
K
Kawai
Yoshiko
Y
Awaya
Akira
A
Gemba
Munekazu
M
D000818:Animals; D015153:Blotting, Western; D002467:Cell Nucleus / Q000473:pathology / Q000648:ultrastructure; D002509:Cephaloridine / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D002511:Cephalosporins / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D004591:Electrophoresis, Polyacrylamide Gel; D004789:Enzyme Activation / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced / Q000201:enzymology / Q000517:prevention & control*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D018374:LLC-PK1 Cells; D008297:Male; D008854:Microscopy, Electron; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D010766:Phosphorylation; D011507:Proteinuria / Q000139:chemically induced; D051381:Rats; D017207:Rats, Sprague-Dawley; D013552:Swine; D013935:Thymic Factor, Circulating / Q000627:therapeutic use*
D002511:Cephalosporins; D013935:Thymic Factor, Circulating; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D020928:Mitogen-Activated Protein Kinases; D002509:Cephaloridine